FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044287878> ?p ?o ?g. }

• W2044287878 endingPage "228" @default.
• W2044287878 startingPage "228" @default.
• W2044287878 abstract "Approximately 2.7 million US individuals are chronically infected with the hepatitis C virus (HCV). As public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage.To examine the clinical benefits and cost-effectiveness of newer treatments for chronic hepatitis C infection in a population of asymptomatic, HCV sero-positive but otherwise healthy individuals.Cost-effectiveness analysis using a Markov model of the natural history of HCV infection and impact of treatment. We used an epidemiologic model to derive a range of natural history parameters that were empirically calibrated to provide a good fit to observed data on both prevalence of HCV seropositivity and time trends in outcomes related to HCV infection.Cohorts of 40-year-old men and women with elevated levels of alanine aminotransferase, positive results on quantitative HCV RNA assays and serologic tests for antibody to HCV, and no histological evidence of fibrosis on liver biopsy.Monotherapy with standard or pegylated interferon alfa-2b; combination therapy with standard or pegylated interferon plus ribavirin.Lifetime costs, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.The probability of patients with chronic HCV developing cirrhosis over a 30-year period ranged from 13% to 46% for men and from 1% to 29% for women. The incremental cost-effectiveness of combination therapy with pegylated interferon for men ranged from 26 000 dollars to 64 000 dollars per QALY for genotype 1 and from 10 000 dollars to 28 000 dollars per QALY for other genotypes; and for women ranged from 32 000 dollars to 90 000 dollars for genotype 1 and from 12 000 dollars to 42 000 dollars for other genotypes. Because the benefits of treatment were realized largely in the form of improvements in health-related quality of life, rather than prolonged survivorship, cost-effectiveness ratios expressed as dollars per year of life were substantially higher. Results were most sensitive to assumptions about the gains and decrements in health-related quality of life associated with treatment.While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions. As the pool of persons eligible for treatment for HCV infection expands to the more general population, it will be imperative for patients and their physicians to consider these assumptions in making individual-level treatment decisions." @default.
• W2044287878 created "2016-06-24" @default.
• W2044287878 creator A5059135593 @default.
• W2044287878 date "2003-07-09" @default.
• W2044287878 modified "2023-10-04" @default.
• W2044287878 title "Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population" @default.
• W2044287878 cites W138424127 @default.
• W2044287878 cites W1512398135 @default.
• W2044287878 cites W1517770332 @default.
• W2044287878 cites W1553514749 @default.
• W2044287878 cites W1969531265 @default.
• W2044287878 cites W1972296017 @default.
• W2044287878 cites W1977797689 @default.
• W2044287878 cites W1978367955 @default.
• W2044287878 cites W1980779398 @default.
• W2044287878 cites W1990781694 @default.
• W2044287878 cites W1994164027 @default.
• W2044287878 cites W2000182266 @default.
• W2044287878 cites W2002345728 @default.
• W2044287878 cites W2005863439 @default.
• W2044287878 cites W2019444858 @default.
• W2044287878 cites W2021831138 @default.
• W2044287878 cites W2026308868 @default.
• W2044287878 cites W2026399029 @default.
• W2044287878 cites W2027269815 @default.
• W2044287878 cites W2028505264 @default.
• W2044287878 cites W2028684272 @default.
• W2044287878 cites W2029585883 @default.
• W2044287878 cites W2036127601 @default.
• W2044287878 cites W2046761147 @default.
• W2044287878 cites W2047556186 @default.
• W2044287878 cites W2053797606 @default.
• W2044287878 cites W2053996087 @default.
• W2044287878 cites W2056689537 @default.
• W2044287878 cites W2058150056 @default.
• W2044287878 cites W2058200448 @default.
• W2044287878 cites W2058361955 @default.
• W2044287878 cites W2059487421 @default.
• W2044287878 cites W2060024172 @default.
• W2044287878 cites W2066586924 @default.
• W2044287878 cites W2075293916 @default.
• W2044287878 cites W2085536840 @default.
• W2044287878 cites W2085684927 @default.
• W2044287878 cites W2091436715 @default.
• W2044287878 cites W2092151915 @default.
• W2044287878 cites W2092472691 @default.
• W2044287878 cites W2094665606 @default.
• W2044287878 cites W2107610652 @default.
• W2044287878 cites W2113576256 @default.
• W2044287878 cites W2114327359 @default.
• W2044287878 cites W2114376411 @default.
• W2044287878 cites W2114800555 @default.
• W2044287878 cites W2119168386 @default.
• W2044287878 cites W2124385839 @default.
• W2044287878 cites W2126959573 @default.
• W2044287878 cites W2127685726 @default.
• W2044287878 cites W2131849574 @default.
• W2044287878 cites W2132290252 @default.
• W2044287878 cites W2133580842 @default.
• W2044287878 cites W2137790765 @default.
• W2044287878 cites W2142285314 @default.
• W2044287878 cites W2151554084 @default.
• W2044287878 cites W2156574153 @default.
• W2044287878 cites W2157611390 @default.
• W2044287878 cites W2159055202 @default.
• W2044287878 cites W2161893095 @default.
• W2044287878 cites W2165167013 @default.
• W2044287878 cites W2165715544 @default.
• W2044287878 cites W2171930710 @default.
• W2044287878 cites W2294950940 @default.
• W2044287878 cites W2313300349 @default.
• W2044287878 cites W2314619766 @default.
• W2044287878 cites W2317554121 @default.
• W2044287878 cites W2327525734 @default.
• W2044287878 cites W2418014884 @default.
• W2044287878 cites W2425668052 @default.
• W2044287878 cites W2470475380 @default.
• W2044287878 cites W2910714963 @default.
• W2044287878 cites W97368551 @default.
• W2044287878 cites W2109253148 @default.
• W2044287878 cites W2208519360 @default.
• W2044287878 doi "https://doi.org/10.1001/jama.290.2.228" @default.
• W2044287878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12851278" @default.
• W2044287878 hasPublicationYear "2003" @default.
• W2044287878 type Work @default.
• W2044287878 sameAs 2044287878 @default.
• W2044287878 citedByCount "240" @default.
• W2044287878 countsByYear W20442878782012 @default.
• W2044287878 countsByYear W20442878782013 @default.
• W2044287878 countsByYear W20442878782014 @default.
• W2044287878 countsByYear W20442878782015 @default.
• W2044287878 countsByYear W20442878782016 @default.
• W2044287878 countsByYear W20442878782017 @default.
• W2044287878 countsByYear W20442878782018 @default.
• W2044287878 countsByYear W20442878782019 @default.
• W2044287878 countsByYear W20442878782020 @default.
• W2044287878 countsByYear W20442878782021 @default.
• W2044287878 countsByYear W20442878782022 @default.

• next